Anteris Technologies Global (AVR) said late Thursday that it has priced a US initial public offering of 14.8 million shares at $6.00 each.
The shares are expected to begin trading Friday on Nasdaq under the ticker "AVR." The company said it expects the offering to close Monday.
The Australian medical device maker also said it has given underwriters a 30-day option to purchase up to 2.2 million additional shares.
The company said the net proceeds from the offering, along with existing cash, will be used for development of its DurAVR transcatheter heart valve, as well as to prepare for and enroll in a study of the device for treating severe aortic stenosis and for other general corporate purposes.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。